Rallybio Corporation (RLYB) — Analyst outlook / Analyst consensus target is. Based on 8 analyst ratings, the consensus is bullish — 4 Buy, 4 Hold.
Analysts estimate Earnings Per Share (EPS) of $-11.36 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-1.33 vs est $-11.36 (beat +88.3%). 2025: actual $-1.59 vs est $-1.80 (beat +11.7%). Analyst accuracy: 0%.
RLYB Analyst Ratings
Buy
Based on 8 analysts giving stock ratings to Rallybio Corporation in the past 3 months
EPS Estimates — RLYB
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$1.33
vs Est –$11.36
▲ 754.1% off
2025
Actual –$1.59
vs Est –$1.80
▲ 13.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — RLYB
88%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.001B
vs Est $0.001B
▼ 5.9% off
2025
Actual $0.001B
vs Est $0.001B
▲ 18.4% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
